Literature DB >> 28636317

Downsizing Proto-oncogene cFos to Short Helix-Constrained Peptides That Bind Jun.

Daniel Baxter1, Samuel R Perry2, Timothy A Hill2, W Mei Kok2, Nathan R Zaccai3, R Leo Brady3, David P Fairlie2, Jody M Mason1.   

Abstract

The oncogenic transcription factor activator protein-1 (AP-1) is a DNA-binding protein that assembles through dimerization of Fos and Jun protein subunits, their leucine-rich helical sequences entwining into a coiled-coil structure. This study reports on downsizing the proto-oncogene cFos protein (380 residues) to shorter peptides (37-25 residues) modified with helix-inducing constraints to enhance binding to Jun. A crystal structure is reported for a 37-residue Fos-derived peptide (FosW) bound to Jun. This guided iterative downsizing of FosW to shorter peptide sequences that were constrained into stable water-soluble α-helices by connecting amino acid side chains to form cyclic pentapeptide components. Structural integrity in the presence and absence of Jun was assessed by circular dichroism spectroscopy, while the thermodynamics of binding to cFos was measured by isothermal titration calorimetry. A 25-residue constrained peptide, one-third shorter yet 25% more helical than the structurally characterized 37-residue Fos-derived peptide, retained 80% of the binding free energy as a result of preorganization in a Jun-binding helix conformation, with the entropy gain (TΔS = +3.2 kcal/mol) compensating for the enthalpy loss. Attaching a cell-penetrating peptide (TAT48-57) and a nuclear localization signal (SV40) promoted cell uptake, localization to the nucleus, and inhibition of the proliferation of two breast cancer cell lines.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28636317     DOI: 10.1021/acschembio.7b00303

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  14 in total

Review 1.  Targeting intracellular protein-protein interactions with macrocyclic peptides.

Authors:  Marina Buyanova; Dehua Pei
Journal:  Trends Pharmacol Sci       Date:  2021-12-13       Impact factor: 14.819

Review 2.  Harnessing the Therapeutic Potential of Biomacromolecules through Intracellular Delivery of Nucleic Acids, Peptides, and Proteins.

Authors:  Yu Tian; Matthew V Tirrell; James L LaBelle
Journal:  Adv Healthc Mater       Date:  2022-03-23       Impact factor: 11.092

3.  N-locking stabilization of covalent helical peptides: Application to Bfl-1 antagonists.

Authors:  Carlo Baggio; Parima Udompholkul; Luca Gambini; Jennifer Jossart; Ahmed F Salem; Maria Håkansson; J Jefferson P Perry; Maurizio Pellecchia
Journal:  Chem Biol Drug Des       Date:  2020-01-20       Impact factor: 2.817

Review 4.  Recent Studies on Ponatinib in Cancers Other Than Chronic Myeloid Leukemia.

Authors:  Francesca Musumeci; Chiara Greco; Giancarlo Grossi; Alessio Molinari; Silvia Schenone
Journal:  Cancers (Basel)       Date:  2018-11-09       Impact factor: 6.639

5.  Recognition of ASF1 by Using Hydrocarbon-Constrained Peptides.

Authors:  May Bakail; Silvia Rodriguez-Marin; Zsófia Hegedüs; Marie E Perrin; Françoise Ochsenbein; Andrew J Wilson
Journal:  Chembiochem       Date:  2019-02-13       Impact factor: 3.164

Review 6.  Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc.

Authors:  Sarah K Madden; Aline Dantas de Araujo; Mara Gerhardt; David P Fairlie; Jody M Mason
Journal:  Mol Cancer       Date:  2021-01-04       Impact factor: 27.401

7.  Intracellular Porphyromonas gingivalis Promotes the Proliferation of Colorectal Cancer Cells via the MAPK/ERK Signaling Pathway.

Authors:  Wenxin Mu; Yiqun Jia; Xiaobing Chen; Haoyu Li; Zhi Wang; Bin Cheng
Journal:  Front Cell Infect Microbiol       Date:  2020-12-23       Impact factor: 5.293

8.  Coiled-coil heterodimers with increased stability for cellular regulation and sensing SARS-CoV-2 spike protein-mediated cell fusion.

Authors:  Tjaša Plaper; Jana Aupič; Petra Dekleva; Fabio Lapenta; Mateja Manček Keber; Roman Jerala; Mojca Benčina
Journal:  Sci Rep       Date:  2021-04-28       Impact factor: 4.379

Review 9.  Selective antagonism of cJun for cancer therapy.

Authors:  Andrew Brennan; James T Leech; Neil M Kad; Jody M Mason
Journal:  J Exp Clin Cancer Res       Date:  2020-09-11

Review 10.  The Role of AP-1 Transcription Factors in Plasma Cell Biology and Multiple Myeloma Pathophysiology.

Authors:  Fengjuan Fan; Klaus Podar
Journal:  Cancers (Basel)       Date:  2021-05-12       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.